Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE7688 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ilepatril (2.5 mg ) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (10 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (35 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (50 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| Losartan-potassium (100 mg) once daily | OTHER | oral administration |
| Name | Type | Description |
|---|---|---|
| AVE7688 | DRUG | oral administration (capsules) |
| Losartan-potassium | DRUG | oral administration (capsules) |
Inclusion Criteria: * Patients with mild-to-moderate, treated or untreated, essential hypertension, as defined by the JNC VII (Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Seventh report ) guidelines who meet the following BP eligibility ...
AVE7688 is an investigational small molecule being developed for the treatment of hypertension, a cardiovascular condition characterized by elevated blood pressure. It is currently in Phase 2 clinical development.
AVE7688 is being developed by Sanofi, a global pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is in Phase 2 clinical development for hypertension.
AVE7688 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not been approved for commercial use.
AVE7688 has been studied in a completed Phase 2 clinical trial with the identifier NCT00284128. This trial enrolled 1,940 participants with mild to moderate hypertension and was conducted across multiple countries, including the United States, Brazil, Canada, and Germany.
AVE7688 is a distinct investigational small molecule developed by Sanofi for hypertension. It is not known to be the same as any other marketed drug, and it is being evaluated specifically for its blood pressure-lowering effects in clinical trials.